Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00 at Canaccord Genuity Group

Atara Biotherapeutics (NASDAQ:ATRA) had its target price upped by equities research analysts at Canaccord Genuity Group from $13.00 to $21.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s target price suggests a potential upside of 64.45% from the company’s current price.

A number of other research firms have also issued reports on ATRA. The Goldman Sachs Group reduced their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a report on Wednesday, July 17th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price objective for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $16.67.

Atara Biotherapeutics Trading Down 10.4 %

NASDAQ ATRA opened at $12.77 on Wednesday. Atara Biotherapeutics has a 1 year low of $6.50 and a 1 year high of $39.50. The company has a market cap of $62.70 million, a PE ratio of -0.50 and a beta of 0.50. The stock’s 50-day moving average price is $8.95 and its two-hundred day moving average price is $10.32.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the firm earned ($16.50) EPS. Research analysts forecast that Atara Biotherapeutics will post -12.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP grew its stake in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares in the last quarter. FMR LLC lifted its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the second quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter worth $53,000. Finally, Redmile Group LLC raised its holdings in shares of Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after purchasing an additional 156,863 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.